In rare cases, weight loss injectables may slow gastric emptying to the extent that it increases the risk of aspiration, particularly in patients with swallowing disorders
Sounds simple
Take a stroll through any shopping area or strip mall, and it seems like the majority of people you see are grappling with obesity
The FDA has released several warnings over the years about being vigilant when buying semaglutide products (Ozempic, Wegovy, Rybelsus)
Simultaneous root-cause work while the medication is active, we address insulin resistance, hormonal imbalances, inflammation, gut health, sleep, and stress so the internal environment improves, not just the number on the scale
Even if the Wegovy negotiation continues, its quite possible it may not cover its use for weight loss unless patients can show they have cardiovascular comorbidities